Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vanda Pharmaceuticals (VNDA)

10.25   0.07 (0.69%) 10-24 22:47
Open: 10.23 Pre. Close: 10.18
High: 10.43 Low: 10.06
Volume: 224,812 Market Cap: 560M
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 270 full-time employees. The firm is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The company offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. The company offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.448 - 10.498 10.498 - 10.543
Low: 9.938 - 9.995 9.995 - 10.048
Close: 10.155 - 10.25 10.25 - 10.336

Technical analysis

as of: 2020-10-23 4:50:15 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 13.12     One year: 15.32
Support: Support1: 9.85    Support2: 9.00
Resistance: Resistance1: 11.23    Resistance2: 13.12
Pivot: 10.54
Moving Average: MA(5): 10.24     MA(20): 10.31
MA(100): 10.77     MA(250): 12.18
MACD: MACD(12,26): 0.07     Signal(9): 0.11
Stochastic oscillator: %K(14,3): 29.19     %D(3): 36.15
RSI: RSI(14): 48.87
52-week: High: 17.85  Low: 7.12  Change(%): -27.9
Average Vol(K): 3-Month: 59080  10-Days: 41067

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
VNDA has closed above bottom band by 31.1%. Bollinger Bands are 4.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 21 Oct 2020
Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020 - Stockhouse

Sat, 10 Oct 2020
Vanda Pharmaceuticals (NASDAQ:VNDA) Rating Increased to Hold at BidaskClub - MarketBeat

Thu, 08 Oct 2020
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Mon, 05 Oct 2020
Is Vanda Pharmaceuticals Inc. (VNDA) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Thu, 01 Oct 2020
We Wouldn’t Rely On Vanda Pharmaceuticals’s (NASDAQ:VNDA) Statutory Earnings As A Guide - Simply Wall St

Tue, 29 Sep 2020
How Will the Market React to Vanda Pharmaceuticals Inc. (VNDA) Stock Getting a Bearish Rating - InvestorsObserver

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 55
Shares Float (M) 40
% Held by Insiders 3.04
% Held by Institutions 98.00
Shares Short (K) 6,230
Shares Short P. Month (K) 6,070

Stock Financials

EPS 2.080
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 7.900
Profit Margin 47.31
Operating Margin 9.99
Return on Assets (ttm) 3.4
Return on Equity (ttm) 31.3
Qtrly Rev. Growth 5.3
Gross Profit (p.s.) 3.709
Sales Per Share 4.403
EBITDA (p.s.) 0.493
Qtrly Earnings Growth -24.40
Operating Cash Flow (M) 39
Levered Free Cash Flow (M) 25

Stock Valuations

PE Ratio 4.93
PEG Ratio 2.07
Price to Book value 1.30
Price to Sales 2.33
Price to Cash Flow 14.40

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.